Company intelligence / Profile preview
Rigel Pharmaceuticals, Inc.
South San Francisco, California, United Statesrigel.com ↗
- Ownership
- Public · RIGL
- Employees
- ~162
- Development stage
- Commercial
01
Overview
Rigel has three approved products: TAVALISSE for chronic immune thrombocytopenia, REZLIDHIA for relapsed or refractory acute myeloid leukemia with IDH1 mutation, and GAVRETO for RET+ non-small cell lung cancer and advanced thyroid cancer. The company is also advancing R289, a dual IRAK1/4 inhibitor for lower-risk myelodysplastic syndrome, which has received Fast Track and Orphan Drug designations from the FDA.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
Eli Lilly (RIPK1 inhibitors)Blueprint Medicines Corporation (acquired US rights to GAVRETO)The University of Texas MD Anderson Cancer Center (REZLIDHIA research)BerGenBioDaiichi Sankyo
04
Financials
- Market cap
- $853.9M
- Total revenue
- $294.3M
- Enterprise value
- $762.3M
Beyond the preview
Go deeper on Rigel Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rigel Pharmaceuticals, Inc..